trending Market Intelligence /marketintelligence/en/news-insights/trending/rHLmbI97cAj7dHO-MlqWqA2 content esgSubNav
In This List

Ablynx establishes US subsidiary

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Ablynx establishes US subsidiary

Ablynx NV established Ablynx Inc., a subsidiary in the U.S.

Daniel Schneider will head the unit as general manager with the goal of commercializing caplacizumab in North America.

If approved by regulatory authorities, caplacizumab would be the first therapeutic specifically indicated to treat acquired thrombotic thrombocytopenic purpura.